atorvastatin + trimetazidine

Atorvastatin + trimetazidine is a combination therapy used primarily for cardiovascular conditions. Atorvastatin is a statin that inhibits HMG-CoA reductase, reducing cholesterol production, while trimetazidine is a metabolic modulator that shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial 3-ketoacyl coenzyme A thiolase. This combination has demonstrated synergistic effects in improving cardiac function, reducing myocardial injury, and decreasing inflammatory markers in patients with coronary heart disease, unstable angina, and cardiac failure. Clinical studies have shown that the combination therapy is more effective than atorvastatin alone in improving left ventricular function, reducing brain natriuretic peptide (BNP) levels, and providing cardioprotection during procedures like percutaneous coronary intervention (PCI).